154 related articles for article (PubMed ID: 29546355)
1. Identification of two potential glycogen synthase kinase 3β inhibitors for the treatment of osteosarcoma.
Lu K; Wang X; Chen Y; Liang D; Luo H; Long L; Hu Z; Bao J
Acta Biochim Biophys Sin (Shanghai); 2018 May; 50(5):456-464. PubMed ID: 29546355
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase 3β promotes osteosarcoma invasion and migration via regulating PTEN and phosphorylation of focal adhesion kinase.
Mai W; Kong L; Yu H; Bao J; Song C; Qu G
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 33969873
[TBL] [Abstract][Full Text] [Related]
3. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
Pardhi T; Vasu K
J Biomol Struct Dyn; 2018 Jan; 36(1):177-194. PubMed ID: 27960601
[TBL] [Abstract][Full Text] [Related]
4. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
Zhu J; Wu Y; Xu L; Jin J
Curr Comput Aided Drug Des; 2020; 16(1):17-30. PubMed ID: 31284868
[TBL] [Abstract][Full Text] [Related]
5. How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
Szamborska-Gbur A; Rutkowska E; Dreas A; Frid M; Vilenchik M; Milik M; Brzózka K; Król M
J Mol Model; 2019 Jan; 25(2):41. PubMed ID: 30673861
[TBL] [Abstract][Full Text] [Related]
6. In silico screening and identification of potential GSK3β inhibitors.
Daggupati T; Pamanji R; Yeguvapalli S
J Recept Signal Transduct Res; 2018 Aug; 38(4):279-289. PubMed ID: 29947280
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the bindings of a class of inhibitors with GSK3β kinase using thermodynamic integration MD simulation and kinase assay.
Hsu CJ; Hsu WC; Lee DJ; Liu AL; Chang CM; Shih HJ; Huang WH; Lee-Chen GJ; Hsieh-Li HM; Lee GC; Sun YC
Chem Biol Drug Des; 2017 Aug; 90(2):272-281. PubMed ID: 28127860
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis and Biological Evaluation of 7-Chloro-9
Andreev S; Pantsar T; Ansideri F; Kudolo M; Forster M; Schollmeyer D; Laufer SA; Koch P
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242571
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of β-catenin.
Shimozaki S; Yamamoto N; Domoto T; Nishida H; Hayashi K; Kimura H; Takeuchi A; Miwa S; Igarashi K; Kato T; Aoki Y; Higuchi T; Hirose M; Hoffman RM; Minamoto T; Tsuchiya H
Oncotarget; 2016 Nov; 7(47):77038-77051. PubMed ID: 27780915
[TBL] [Abstract][Full Text] [Related]
10. Theoretical studies on the selective mechanisms of GSK3β and CDK2 by molecular dynamics simulations and free energy calculations.
Zhao S; Zhu J; Xu L; Jin J
Chem Biol Drug Des; 2017 Jun; 89(6):846-855. PubMed ID: 27863047
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors.
Arfeen M; Bhagat S; Patel R; Prasad S; Roy I; Chakraborti AK; Bharatam PV
Eur J Med Chem; 2016 Oct; 121():727-736. PubMed ID: 27423119
[TBL] [Abstract][Full Text] [Related]
12. Identifying potential Alzheimer's disease therapeutics through GSK-3β inhibition: A molecular docking and dynamics approach.
Mohammadi Y; Emadi R; Maddahi A; Shirdel S; Morowvat MH
Comput Biol Chem; 2024 Aug; 111():108095. PubMed ID: 38805865
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of valmerins as dual inhibitors of GSK3β/CDK5.
Li X; Wang X; Tian Z; Zhao H; Liang D; Li W; Qiu Y; Lu S
J Mol Model; 2014 Sep; 20(9):2407. PubMed ID: 25142337
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of (aza)indolyl maleimide-based covalent inhibitors of glycogen synthase kinase 3β.
Yang Z; Liu H; Pan B; He F; Pan Z
Org Biomol Chem; 2018 Jun; 16(22):4127-4140. PubMed ID: 29781013
[TBL] [Abstract][Full Text] [Related]
15. EZH2 promotes the progression of osteosarcoma through the activation of the AKT/GSK3β pathway.
Wan D; Han X; Zhang C; Zhang Y; Ma Y; Wang G
Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1179-1186. PubMed ID: 35818168
[TBL] [Abstract][Full Text] [Related]
16. Application of Fragment-Based de Novo Design to the Discovery of Selective Picomolar Inhibitors of Glycogen Synthase Kinase-3 Beta.
Park H; Shin Y; Kim J; Hong S
J Med Chem; 2016 Oct; 59(19):9018-9034. PubMed ID: 27676184
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Glycogen Synthase Kinase Inhibitors That Regulate Cytochrome P450 Expression in Primary Human Hepatocytes by Activation of β-Catenin, Aryl Hydrocarbon Receptor and Pregnane X Receptor Signaling.
Briolotti P; Chaloin L; Balaguer P; Da Silva F; Tománková V; Pascussi JM; Duret C; Fabre JM; Ramos J; Klieber S; Maurel P; Daujat-Chavanieu M; Gerbal-Chaloin S
Toxicol Sci; 2015 Nov; 148(1):261-75. PubMed ID: 26259606
[TBL] [Abstract][Full Text] [Related]
18. The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer.
Gao Y; Ye DY; Zhou WC; Chu Y
Eur J Med Chem; 2017 Jul; 135():370-381. PubMed ID: 28460311
[TBL] [Abstract][Full Text] [Related]
19. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3β inhibitors.
Lozinskaya NA; Babkov DA; Zaryanova EV; Bezsonova EN; Efremov AM; Tsymlyakov MD; Anikina LV; Zakharyascheva OY; Borisov AV; Perfilova VN; Tyurenkov IN; Proskurnina MV; Spasov AA
Bioorg Med Chem; 2019 May; 27(9):1804-1817. PubMed ID: 30902399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
